The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Zealand Pharma AS's Revenue for the
three
months ended in Mar. 2026 was $5 Mil. Zealand Pharma AS's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0 Mil.
Hence, Zealand Pharma AS's Receivables Turnover for the
three
months ended in Mar. 2026 was 12.73.
Zealand Pharma AS (OTCPK:ZLDPF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Zealand Pharma AS Receivables Turnover Related Terms
Zealand Pharma AS Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Zealand Pharma AS's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZLDPF vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Zealand Pharma AS's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zealand Pharma AS Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Zealand Pharma AS's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zealand Pharma AS (ZLDPF) has a Receivables Turnover of 12.73 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Zealand Pharma AS and its competitors. According to the industry distribution chart, Zealand Pharma AS ranks #3 out of 839 companies in the Biotechnology industry, placing it in the top 0.40000000000001%.
Is Zealand Pharma AS's Receivables Turnover too high?
Zealand Pharma AS's current Receivables Turnover is 12.73. The Biotechnology industry median Receivables Turnover is 5.29. Zealand Pharma AS's value of 12.73 is 140.6% above this industry median. Based on the distribution chart, Zealand Pharma AS ranks #3 out of 839 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zealand Pharma AS has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zealand Pharma AS ranks #3 out of 839 companies for Receivables Turnover. This places Zealand Pharma AS in the top 0% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.29. Zealand Pharma AS's value of 12.73 is 140.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zealand Pharma AS's current Receivables Turnover of 12.73 is 140.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Zealand Pharma AS and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zealand Pharma AS's current Receivables Turnover is 12.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (ZLDPF) is currently considered Possible Value Trap. The stock's GF Value™ is $1,951.26, compared to a current price of $44.86 — trading 97.7% below its estimated fair value. The current Receivables Turnover is 12.73 and 140.6% above the Biotechnology industry median of 5.29. Zealand Pharma AS's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPF), the current Receivables Turnover is 12.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zealand Pharma AS (ZLDPF) Overvalued in 2026?
Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued.
The current stock price of $44.86 is trading 97.7% below its estimated GF Value™ of $1,951.26.
GuruFocus considers Zealand Pharma AS to be Possible Value Trap.
Key valuation signals for ZLDPF:
Receivables Turnover: 12.73
GF Value™: $1,951.26 vs. price of $44.86 (97.7% below fair value)
Industry Position: 140.6% above the Biotechnology median (#3 of 839)
No single metric tells the full story. See the ZLDPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
62GF Score
Get the complete analysis for ZLDPF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLDPF has been successfully added to your 
